Roche bets again on Ionis in Huntington’s, Alzheimer's
Roche is again pairing up with its decadelong partner Ionis Pharmaceuticals, paying $60 million upfront for the exclusive rights to two RNA assets, the companies said Wednesday morning.
The deal centers around Huntington’s disease and Alzheimer’s disease. The duo originally came together in 2013 for another Huntington’s program, tominersen, which is currently in a Phase II study, and again in 2018 for IgA nephropathy and a leading cause of blindness known as geographic atrophy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.